4018.SR
SinkerAlmoosa Health Company · Healthcare · Saudi Arabia · $1.3B cap · $642K/day traded
SAR 106.00 +3.3% · close 5 Nov · scored 7 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 7 Nov 2026, the MoatMap Score for Almoosa Health Company (4018.SR) is 30/100, ranked against 25,000+ stocks in 38 markets (Quality 49, Value 40, Momentum 31, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT ALMOOSA HEALTH COMPANY
Read
Almoosa Health Company operates as a private healthcare provider in the Kingdom of Saudi Arabia. It stores medical items and sells medicine, cosmetics, and disposable medical items.
FINANCIAL SUMMARY (SAR)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.2B | 1.4B | 17.8% | 1.5B | 1.6B | 2.0B | 17.8% |
| EPS (SAR) | — | 1.11 | 5.36 | 381.2% | 4.57 | 3.75 | 4.60 | -7.3% |
| Shares | 44.3M | 44.3M | 44.3M | 0.0% | 44.3M | — | — | — |
| Debt | 1.2B | 1.4B | 812.5M | -18.3% | 1.5B | — | — | — |
| Equity | 609.6M | 626.3M | 1.9B | 77.7% | — | — | — | — |
| Op CF | — | 139.7M | 180.8M | 29.5% | 167.6M | — | — | — |
| Inv CF | — | -218.2M | -617.0M | — | — | — | — | — |
| Fin CF | — | 100.9M | 436.3M | — | — | — | — | — |
Made a new 52-week low 8 trading days ago, 46% below its 52-week high. The fall has not stopped yet.
Calmer than 73% of stocks we rank over the past year (volatility 30% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4018.SR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| 4018.SR | Almoosa Health Company(you) | $1.3B | 30 |
| 4004.SR | Dallah Healthcare Company | $1.9B | 34 |
| 4017.SR | Dr. Soliman Abdel Kader Fakeeh Hospital Company | $1.9B | 42 |
| 4005.SR | National Medical Care Company | $1.2B | 62 |
| 4007.SR | Al Hammadi Holding Company | $925M | 68 |
| 4019.SR | Specialized Medical Company | $875M | 69 |
| 9627.SR | Twareat Medical Care Company | $96M | 30 |
| 4009.SR | Middle East Healthcare Company | $563M | 73 |
| 9544.SR | Future Care Trading Co. | $161M | 50 |
| 4013.SR | Dr. Sulaiman Al Habib Medical Services Group Company | $20.1B | 45 |
Peer medians: ROE 15.6% · P/E 16.2x · Gross margin 32.6%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.